Literature DB >> 24625365

Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the rat.

Xiaohong Tracey Gan1, Grace Ettinger1, Cathy X Huang1, Jeremy P Burton1, James V Haist1, Venkatesh Rajapurohitam1, James E Sidaway1, Glynn Martin1, Gregory B Gloor1, Jonathan R Swann1, Gregor Reid1, Morris Karmazyn2.   

Abstract

BACKGROUND: Probiotics are extensively used to promote gastrointestinal health, and emerging evidence suggests that their beneficial properties can extend beyond the local environment of the gut. Here, we determined whether oral probiotic administration can alter the progression of postinfarction heart failure. METHODS AND
RESULTS: Rats were subjected to 6 weeks of sustained coronary artery occlusion and administered the probiotic Lactobacillus rhamnosus GR-1 or placebo in the drinking water ad libitum. Culture and 16s rRNA sequencing showed no evidence of GR-1 colonization or a significant shift in the composition of the cecal microbiome. However, animals administered GR-1 exhibited a significant attenuation of left ventricular hypertrophy based on tissue weight assessment and gene expression of atrial natriuretic peptide. Moreover, these animals demonstrated improved hemodynamic parameters reflecting both improved systolic and diastolic left ventricular function. Serial echocardiography revealed significantly improved left ventricular parameters throughout the 6-week follow-up period including a marked preservation of left ventricular ejection fraction and fractional shortening. Beneficial effects of GR-1 were still evident in those animals in which GR-1 was withdrawn at 4 weeks, suggesting persistence of the GR-1 effects after cessation of therapy. Investigation of mechanisms showed a significant increase in the leptin:adiponectin plasma concentration ratio in rats subjected to coronary ligation, which was abrogated by GR-1. Metabonomic analysis showed differences between sham control and coronary artery ligated hearts particularly with respect to preservation of myocardial taurine levels.
CONCLUSIONS: The study suggests that probiotics offer promise as a potential therapy for the attenuation of heart failure.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  cardiomegaly; heart failure; microbiota; probiotics

Mesh:

Year:  2014        PMID: 24625365     DOI: 10.1161/CIRCHEARTFAILURE.113.000978

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  90 in total

1.  Bifidobacterium animalis subsp. lactis 420 mitigates the pathological impact of myocardial infarction in the mouse.

Authors:  C A Danilo; E Constantopoulos; L A McKee; H Chen; J A Regan; Y Lipovka; S Lahtinen; L K Stenman; T-V V Nguyen; K P Doyle; M J Slepian; Z I Khalpey; J P Konhilas
Journal:  Benef Microbes       Date:  2017-04-14       Impact factor: 4.205

Review 2.  Association between Bacterial Infection and Peripheral Vascular Disease: A Review.

Authors:  Jacek Budzyński; Joanna Wiśniewska; Marek Ciecierski; Anna Kędzia
Journal:  Int J Angiol       Date:  2015-03-23

Review 3.  The microbiome of the urinary tract--a role beyond infection.

Authors:  Samantha A Whiteside; Hassan Razvi; Sumit Dave; Gregor Reid; Jeremy P Burton
Journal:  Nat Rev Urol       Date:  2015-01-20       Impact factor: 14.432

4.  Shining light on microbial signaling to distant organs.

Authors:  Fredrik Bäckhed
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-29       Impact factor: 11.205

Review 5.  Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health.

Authors:  Carl D Koch; Mark T Gladwin; Bruce A Freeman; Jon O Lundberg; Eddie Weitzberg; Alison Morris
Journal:  Free Radic Biol Med       Date:  2016-12-16       Impact factor: 7.376

Review 6.  The gut microbiome and heart failure: A better gut for a better heart.

Authors:  Maxime Branchereau; Rémy Burcelin; Christophe Heymes
Journal:  Rev Endocr Metab Disord       Date:  2019-12       Impact factor: 6.514

Review 7.  Antihypertensive Effects of Probiotics.

Authors:  Iñaki Robles-Vera; Marta Toral; Miguel Romero; Rosario Jiménez; Manuel Sánchez; Francisco Pérez-Vizcaíno; Juan Duarte
Journal:  Curr Hypertens Rep       Date:  2017-04       Impact factor: 5.369

Review 8.  Targeting the Microbiome in Heart Failure.

Authors:  Allyson Zabell; W H Wilson Tang
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-04

Review 9.  Microbiota and metabolic diseases.

Authors:  Alessia Pascale; Nicoletta Marchesi; Cristina Marelli; Adriana Coppola; Livio Luzi; Stefano Govoni; Andrea Giustina; Carmine Gazzaruso
Journal:  Endocrine       Date:  2018-05-02       Impact factor: 3.633

Review 10.  ACE2 and Microbiota: Emerging Targets for Cardiopulmonary Disease Therapy.

Authors:  Colleen T Cole-Jeffrey; Meng Liu; Michael J Katovich; Mohan K Raizada; Vinayak Shenoy
Journal:  J Cardiovasc Pharmacol       Date:  2015-12       Impact factor: 3.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.